This protocol covers the management of hypopharyngeal squamous cell carcinoma presenting at tumour stage cT4b, with nodal stage cN0–N3 and no distant metastasis cM0. This staging combination defines a specific, well-characterised clinical population for which evidence-based treatment pathways have been established.

Clinical Scenario

The presentation involves hypopharyngeal squamous cell carcinoma at tumour stage cT4b, spanning the full range of nodal involvement from cN0 through cN3, with confirmed absence of distant metastasis (cM0). Accurate staging across all three axes — tumour, node, and metastasis — is central to selecting the appropriate treatment pathway.

Treatment Goals

The key clinical objective in this setting is achieving complete or partial tumour response. The protocol defines the conditions under which each treatment approach is applied and the response criteria used to guide subsequent management.

Treatment Approach — Partial Overview

Management of this staging includes evidence-based locoregional and systemic options — among them induction chemotherapy-based strategies and concomitant chemoradiotherapy, alongside palliative pathways for appropriately selected patients.

Full regimen details, sequencing criteria, and eligibility conditions are in the structured protocol below.

References

DOI: 10.1016/j.annonc.2020.07.011

cT4b cN0−3 cM0
Induction ChT followed by RT for responders (T and N) [IV, B]
Concomitant CRT (T and N) [IV, B]
Palliative treatment: systemic ChT/immunotherapy and/or palliative RT and/or BSC [IV, B]
The standard of care for ChT is cisplatin at a dose of 100 mg/m2 given on days 1, 22 and 43 of concomitant RT (70 Gy) [II, A].
The introduction of taxane/platinum/5-FU (TPF) combinations has proven superior to platinum/5-FU schedules and TPF is now the standard induction ChT regimen [I, A].

View source ↗

Treatment of Hypopharyngeal Squamous Cell Carcinoma — Tumour Stage cT4b, cN0–N3, cM0

References